Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
1. Does transplant medicine have a new blood test that is better than creatinine?
— Nephrology Jrnl Club (@NephJC) July 1, 2022
Aye aye ADMIRAL 🫡
Join us as we recap last week's #NephJC chat on this edition of #TenTweetNephJC brought to you by @jamiekwillows and @michaelturk6 pic.twitter.com/gAS70VKG8i